Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest move in its acquisition spree as it expands into cancer and autoimmune diseases.
Published
Original News Source
Bloomberg — Business
Source Website
www.bloomberg.com ↗
Content & Media Rights
Deirdre Hipwell / Bloomberg — Business
Editorial Publisher
360 NEWS (Independent Media)
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest move in its acquisition spree as it expands into cancer and autoimmune diseases.
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].

